Cargando…
Amniotic fluid embolism incidence, risk factors and outcomes: a review and recommendations
BACKGROUND: Amniotic fluid embolism (AFE) is a rare but severe complication of pregnancy. A recent systematic review highlighted apparent differences in the incidence, with studies estimating the incidence of AFE to be more than three times higher in North America than Europe. The aim of this study...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305555/ https://www.ncbi.nlm.nih.gov/pubmed/22325370 http://dx.doi.org/10.1186/1471-2393-12-7 |
_version_ | 1782227095569563648 |
---|---|
author | Knight, Marian Berg, Cynthia Brocklehurst, Peter Kramer, Michael Lewis, Gwyneth Oats, Jeremy Roberts, Christine L Spong, Catherine Sullivan, Elizabeth van Roosmalen, Jos Zwart, Joost |
author_facet | Knight, Marian Berg, Cynthia Brocklehurst, Peter Kramer, Michael Lewis, Gwyneth Oats, Jeremy Roberts, Christine L Spong, Catherine Sullivan, Elizabeth van Roosmalen, Jos Zwart, Joost |
author_sort | Knight, Marian |
collection | PubMed |
description | BACKGROUND: Amniotic fluid embolism (AFE) is a rare but severe complication of pregnancy. A recent systematic review highlighted apparent differences in the incidence, with studies estimating the incidence of AFE to be more than three times higher in North America than Europe. The aim of this study was to examine population-based regional or national data from five high-resource countries in order to investigate incidence, risk factors and outcomes of AFE and to investigate whether any variation identified could be ascribed to methodological differences between the studies. METHODS: We reviewed available data sources on the incidence of AFE in Australia, Canada, the Netherlands, the United Kingdom and the USA. Where information was available, the risk factors and outcomes of AFE were examined. RESULTS: The reported incidence of AFE ranged from 1.9 cases per 100 000 maternities (UK) to 6.1 per 100 000 maternities (Australia). There was a clear distinction between rates estimated using different methodologies. The lowest estimated incidence rates were obtained through validated case identification (range 1.9-2.5 cases per 100 000 maternities); rates obtained from retrospective analysis of population discharge databases were significantly higher (range 5.5-6.1 per 100 000 admissions with delivery diagnosis). Older maternal age and induction of labour were consistently associated with AFE. CONCLUSIONS: Recommendation 1: Comparisons of AFE incidence estimates should be restricted to studies using similar methodology. The recommended approaches would be either population-based database studies using additional criteria to exclude false positive cases, or tailored data collection using existing specific population-based systems. Recommendation 2: Comparisons of AFE incidence between and within countries would be facilitated by development of an agreed case definition and an agreed set of criteria to minimise inclusion of false positive cases for database studies. Recommendation 3: Groups conducting detailed population-based studies on AFE should develop an agreed strategy to allow combined analysis of data obtained using consistent methodologies in order to identify potentially modifiable risk factors. Recommendation 4: Future specific studies on AFE should aim to collect information on management and longer-term outcomes for both mothers and infants in order to guide best practice, counselling and service planning. |
format | Online Article Text |
id | pubmed-3305555 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-33055552012-03-16 Amniotic fluid embolism incidence, risk factors and outcomes: a review and recommendations Knight, Marian Berg, Cynthia Brocklehurst, Peter Kramer, Michael Lewis, Gwyneth Oats, Jeremy Roberts, Christine L Spong, Catherine Sullivan, Elizabeth van Roosmalen, Jos Zwart, Joost BMC Pregnancy Childbirth Research Article BACKGROUND: Amniotic fluid embolism (AFE) is a rare but severe complication of pregnancy. A recent systematic review highlighted apparent differences in the incidence, with studies estimating the incidence of AFE to be more than three times higher in North America than Europe. The aim of this study was to examine population-based regional or national data from five high-resource countries in order to investigate incidence, risk factors and outcomes of AFE and to investigate whether any variation identified could be ascribed to methodological differences between the studies. METHODS: We reviewed available data sources on the incidence of AFE in Australia, Canada, the Netherlands, the United Kingdom and the USA. Where information was available, the risk factors and outcomes of AFE were examined. RESULTS: The reported incidence of AFE ranged from 1.9 cases per 100 000 maternities (UK) to 6.1 per 100 000 maternities (Australia). There was a clear distinction between rates estimated using different methodologies. The lowest estimated incidence rates were obtained through validated case identification (range 1.9-2.5 cases per 100 000 maternities); rates obtained from retrospective analysis of population discharge databases were significantly higher (range 5.5-6.1 per 100 000 admissions with delivery diagnosis). Older maternal age and induction of labour were consistently associated with AFE. CONCLUSIONS: Recommendation 1: Comparisons of AFE incidence estimates should be restricted to studies using similar methodology. The recommended approaches would be either population-based database studies using additional criteria to exclude false positive cases, or tailored data collection using existing specific population-based systems. Recommendation 2: Comparisons of AFE incidence between and within countries would be facilitated by development of an agreed case definition and an agreed set of criteria to minimise inclusion of false positive cases for database studies. Recommendation 3: Groups conducting detailed population-based studies on AFE should develop an agreed strategy to allow combined analysis of data obtained using consistent methodologies in order to identify potentially modifiable risk factors. Recommendation 4: Future specific studies on AFE should aim to collect information on management and longer-term outcomes for both mothers and infants in order to guide best practice, counselling and service planning. BioMed Central 2012-02-10 /pmc/articles/PMC3305555/ /pubmed/22325370 http://dx.doi.org/10.1186/1471-2393-12-7 Text en Copyright ©2012 Knight et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Knight, Marian Berg, Cynthia Brocklehurst, Peter Kramer, Michael Lewis, Gwyneth Oats, Jeremy Roberts, Christine L Spong, Catherine Sullivan, Elizabeth van Roosmalen, Jos Zwart, Joost Amniotic fluid embolism incidence, risk factors and outcomes: a review and recommendations |
title | Amniotic fluid embolism incidence, risk factors and outcomes: a review and recommendations |
title_full | Amniotic fluid embolism incidence, risk factors and outcomes: a review and recommendations |
title_fullStr | Amniotic fluid embolism incidence, risk factors and outcomes: a review and recommendations |
title_full_unstemmed | Amniotic fluid embolism incidence, risk factors and outcomes: a review and recommendations |
title_short | Amniotic fluid embolism incidence, risk factors and outcomes: a review and recommendations |
title_sort | amniotic fluid embolism incidence, risk factors and outcomes: a review and recommendations |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305555/ https://www.ncbi.nlm.nih.gov/pubmed/22325370 http://dx.doi.org/10.1186/1471-2393-12-7 |
work_keys_str_mv | AT knightmarian amnioticfluidembolismincidenceriskfactorsandoutcomesareviewandrecommendations AT bergcynthia amnioticfluidembolismincidenceriskfactorsandoutcomesareviewandrecommendations AT brocklehurstpeter amnioticfluidembolismincidenceriskfactorsandoutcomesareviewandrecommendations AT kramermichael amnioticfluidembolismincidenceriskfactorsandoutcomesareviewandrecommendations AT lewisgwyneth amnioticfluidembolismincidenceriskfactorsandoutcomesareviewandrecommendations AT oatsjeremy amnioticfluidembolismincidenceriskfactorsandoutcomesareviewandrecommendations AT robertschristinel amnioticfluidembolismincidenceriskfactorsandoutcomesareviewandrecommendations AT spongcatherine amnioticfluidembolismincidenceriskfactorsandoutcomesareviewandrecommendations AT sullivanelizabeth amnioticfluidembolismincidenceriskfactorsandoutcomesareviewandrecommendations AT vanroosmalenjos amnioticfluidembolismincidenceriskfactorsandoutcomesareviewandrecommendations AT zwartjoost amnioticfluidembolismincidenceriskfactorsandoutcomesareviewandrecommendations |